TMS vs Spravato vs Medication

When someone
has depression that isn’t adequately helped by one treatment, clinicians choose among evidence-based options based on the person’s history, safety, goals, and logistics. At Redbud, we commonly consider three high-value pathways:
Transcranial Magnetic Stimulation (TMS), Spravato® (esketamine), and advanced medication strategies. Below is a clear, practical comparison to help patients and families understand how these options differ and how they may be combined.
Quick Snapshot
- Medications - oral or injectable agents prescribed and monitored over weeks to months. Widely accessible and often covered by insurance; good first-line or augmentation option, but may require multiple trials.
- Spravato (esketamine) - an in-clinic nasal spray that can produce rapid antidepressant effects (hours–days) for treatment-resistant depression; requires supervised dosing and same-day observation. Coverage varies by plan.
- TMS (standard & accelerated) - non-invasive brain stimulation delivered in the clinic. Standard TMS is typically given daily over several weeks (insurance often covers when criteria are met); accelerated protocols compress treatments (5-day, 1-day, or a new flexible 6 half-day option) for patients who need faster calendar responses, but usually on a self-pay basis.
When each option is appropriate
Medication management
- Appropriate for: Most patients as first-line treatment or as ongoing maintenance. Also used as an augmentation when a partial response occurs. Especially useful for people who prefer oral therapy, have good tolerability, and for whom insurance coverage is essential.
- Consider advanced medications (e.g., lithium or MAOIs) for treatment-resistant cases when safer, well-monitored options are needed - Redbud emphasizes careful monitoring and evidence-based choice.
Spravato (esketamine)
Appropriate for: Adults with treatment-resistant depression who have not improved with adequate medication and psychotherapy trials and who require more rapid symptom relief. It’s delivered in a clinic, under supervision, and can be lifesaving for people with severe symptoms. Because it is administered in-clinic with required observation and same-day driving restrictions, candidacy and logistics are important.
TMS (standard & accelerated)
Appropriate for: People with major depressive disorder who have not achieved adequate benefit from medications and/or psychotherapy, or those who prefer a non-systemic (non-drug) approach. Standard TMS is a strong option when insurance coverage is needed; accelerated options suit patients who need a faster calendar treatment (travel or life constraints). Redbud offers standard TMS plus accelerated choices (one-day, 5-day, and a flexible 6 half-day protocol) and screens candidacy carefully.
Timelines for benefit (realistic expectations)
Medications: Most antidepressants require 4–8 weeks (or longer) to show clear benefit; some augmentation strategies or specific agents may take longer and require careful titration. Monitoring and follow-up are essential.
Spravato: Can produce rapid symptom shifts in hours–days for some patients, with benefits often building over repeated sessions. Because of acute effects, sessions are supervised and require post-dose observation.
TMS:
- Standard TMS - typically delivered daily across 6–8 weeks (≈30–36 sessions) with improvements often evident over weeks.
- Accelerated TMS - compressed schedules (5-day or 1-day) or the new flexible 6 half-day protocol can shorten calendar time to a course (days to a couple of weeks), though clinical responses can still evolve over days to weeks after treatment.
Side Effects & Safety Profiles
Medications: Side effects depend on the drug class (weight change, sexual side effects, GI symptoms, sedation, activation, and bloodwork requirements). Certain older agents (MAOIs, lithium) or augmenting agents require lab monitoring (lithium levels, EKGs, liver/renal labs) and specialist oversight. Redbud emphasizes safety monitoring for advanced medication strategies.
Spravato: Common short-term effects include dissociation, dizziness, nausea, sleepiness, and transient blood-pressure increases. Because of these effects patients must be observed after dosing and cannot drive the same day. Clinics monitor vitals and manage acute side effects.
TMS: Usually well tolerated; common early effects are scalp discomfort or headache and transient fatigue. Rarely, TMS carries a seizure risk - clinics perform safety screening to minimize this. Accelerated/one-day protocols are more intensive and can produce greater short-term tiredness; candidacy screening and monitoring are critical.
Cost & Coverage Differences
Medications: Typically covered by insurance (subject to formulary and copays). Advanced or branded agents and complex regimens may have higher out-of-pocket costs. Lab monitoring and clinic visits may add costs.
Spravato: Coverage varies by insurer - the clinic verifies benefits and manages prior authorizations, but patient responsibility depends on plan terms and copays/deductibles. Because the medication and clinic time can be expensive, Redbud recommends a benefits check before starting.
TMS:
- Standard TMS is often covered by major insurers when strict clinical criteria are met; Redbud runs benefits checks and prior authorization for eligibility.
- Accelerated TMS (5-day, 1-day, and the 6 half-day protocol) is usually self-pay. Example pricing used by Redbud: 5-day ≈ $5,000; 1-day ≈ $2,500 (sample figures - Redbud provides written estimates tailored to each patient). Financing/ payment-plan options (third-party vendors) are sometimes available.
Combining Treatments
These options are not mutually exclusive. Clinicians often:
- Start with medication adjustments while assessing candidacy for TMS or Spravato.
- Use Spravato for rapid symptom control while planning longer-term strategies (TMS, meds, psychotherapy).
- Combine TMS with ongoing psychotherapy and medications when indicated; coordinated care improves safety and outcomes. Redbud’s clinician-led model focuses on shared decision-making to tailor sequencing and combination to the person’s needs.
Learn More: Compare Treatments
Practical logistics for Fredericksburg patients
Travel & scheduling: One-day protocols are appealing to regional patients who travel; Redbud’s flexible 6 half-day option is designed for people with scheduling constraints across weeks. Redbud serves Fredericksburg and nearby counties and considers regional travel when recommending a protocol.
Cost & payment: Accelerated options are usually self-pay; one-day programs are typically priced lower than multi-week standard courses, but expect an out-of-pocket commitment (example, typical pricing for one-day programs is in the $2,500 range - Redbud provides written estimates at consult). For standard TMS, Redbud handles benefits checks and prior authorization when insurance may cover care.
Comparison table
| Option | When to consider | Timeline for benefit | Key side effects | Typical coverage |
|---|---|---|---|---|
| Medications | First-line; augmentation; patient preference | 4–8+ weeks | Class-specific (GI, sexual, sedation, metabolic) | Generally covered; copays apply |
| Spravato | Treatment-resistant depression needing faster relief | Hours–days (over repeated sessions) | Dissociation, BP rise, sedation — requires observation; no driving same day | Coverage varies; verify benefits/prior auth |
| TMS (standard) | Medication nonresponse or non-drug preference | Weeks (≈6–8 weeks) | Scalp pain/headache, rare seizure risk | Often covered with criteria/prior auth |
| Accelerated TMS (1-day/5-day/6 half-day) | Need rapid calendar response or travel constraint | Days–weeks (responses vary) | More fatigue, scalp ache; careful screening needed | Usually self-pay (5-day ≈ $5k; 1-day ≈ $2.5k) |
Can I try Spravato and TMS together?
Sometimes - clinicians coordinate timing and monitoring, and combinations are considered on a case-by-case basis depending on safety and goals.
Which is “most effective”?
Effectiveness varies by person and prior treatment history. TMS and Spravato both have evidence for treatment-resistant depression; medications remain foundational and are effective for many people. The best choice is individualized.















